Controlled Fab-arm exchange for the generation of stable bispecific IgG1

Nature Protocols

Volumn 9, Issue 10, 2014, Pages 2450-2463

  Labrijn, Aran F ^a   Meesters, Joyce I ^a   Priem, Patrick ^a   De Jong, Rob N ^a   Van Den Bremer, Ewald T J ^a   Van Kampen, Muriel D ^a   Gerritsen, Arnout F ^a   Schuurman, Janine ^a   Parren, Paul W H I ^a  

^a GENMAB   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4;

AFFINITY CHROMATOGRAPHY; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; CAPILLARY ELECTROPHORESIS; CONTROLLED FAB ARM EXCHANGE; DISULFIDE BOND; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; MASS SPECTROMETRY; MOLECULAR CLONING; OXIDATION REDUCTION STATE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 84963959117     PISSN: 17542189     EISSN: 17502799     Source Type: Journal    
DOI: 10.1038/nprot.2014.169     Document Type: Article

References (31)

1. Kontermann, R. Dual targeting strategies with bispecific antibodies. MAbs 4, 182-197 (2012).
2. Labrijn, A.F. et al. Species-specific determinants in the IgG CH3 domain enable Fab-arm exchange by affecting the noncovalent CH3-CH3 interaction strength. J. Immunol. 187, 3238-3246 (2011).
3. Schuurman, J. et al. Normal human immunoglobulin G4 is bispecific: it has two different antigen-combining sites. Immunology 97, 693-698 (1999).
4. van der Neut Kolfschoten, M. et al. Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317, 1554-1557 (2007).
5. Gramer, M.J. et al. Production of stable bispecific IgG1 by controlled Fab-arm exchange: scalability from bench to large-scale manufacturing by application of standard approaches. MAbs 5, 962-973 (2013).
6. Labrijn, A.F. et al. Efficient generation of stable bispecific IgG1 by controlled Fab-arm exchange. Proc. Natl. Acad. Sci. USA 110, 5145-5150 (2013).
7. Kabat, E.A., Wu, T.T., Perry, H.M., Gottesman, K.S. & Foeller, C. Sequences of Proteins of Immunological Interest 5th edn. (US Department of Health and Human Services, Public Health Services, National Institutes of Health, 1991).
8. Birch, J.R. & Racher, A.J. Antibody production. Adv. Drug Deliv. Rev. 58, 671-685 (2006).
9. Demarest, S.J. & Glaser, S.M. Antibody therapeutics, antibody engineering, and the merits of protein stability. Curr. Opin. Drug Discov. Devel. 11, 675-687 (2008).
10. Lowe, D. et al. Aggregation, stability, and formulation of human antibody therapeutics. Adv. Protein Chem. Struct. Biol. 84, 41-61 (2011).
11. Chames, P. & Baty, D. Bispecific antibodies for cancer therapy. Curr. Opin. Drug Discov. Devel. 12, 276-283 (2009).
12. Chan, A.C. & Carter, P.J. Therapeutic antibodies for autoimmunity and inflammation. Nat. Rev. Immunol. 10, 301-316 (2010).
13. Wu, C. et al. Molecular construction and optimization of anti-human IL-1alpha/beta dual variable domain immunoglobulin (DVD-Ig) molecules. MAbs 1, 339-347 (2009).
14. Milstein, C. & Cuello, A.C. Hybrid hybridomas and their use in immunohistochemistry. Nature 305, 537-540 (1983).
15. Lewis, S.M. et al. Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface. Nat. Biotechnol. 32, 191-198 (2014).
16. Lindhofer, H., Mocikat, R., Steipe, B. & Thierfelder, S. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies. J. Immunol. 155, 219-225 (1995).
17. Merchant, A.M. et al. An efficient route to human bispecific IgG. Nat. Biotechnol. 16, 677-681 (1998).
18. Schaefer, W. et al. Immunoglobulin domain crossover as a generic approach for the production of bispecific IgG antibodies. Proc. Natl. Acad. Sci. USA 108, 11187-11192 (2011).
19. Choi, H.J., Kim, Y.J., Lee, S. & Kim, Y.S. A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity. Mol. Cancer Ther. 12, 2748-2759 (2013).
20. Davis, J.H. et al. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies. Protein Eng. Des. Sel. 23, 195-202 (2010).
21. Gunasekaran, K. et al. Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG. J. Biol. Chem. 285, 19637-19646 (2010).
22. Moore, G.L. et al. A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens. MAbs 3, 546-557 (2011).
23. Spreter Von Kreudenstein, T., Lario, P.I. & Dixit, S.B. Protein engineering and the use of molecular modeling and simulation: the case of heterodimeric Fc engineering. Methods 65, 77-94 (2014).
24. Strop, P. et al. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair. J. Mol. Biol. 420, 204-219 (2012).
25. Shatz, W. et al. Knobs-into-holes antibody production in mammalian cell lines reveals that asymmetric afucosylation is sufficient for full antibody-dependent cellular cytotoxicity. MAbs 5, 872-881 (2013).
26. Spiess, C. et al. Bispecific antibodies with natural architecture produced by co-culture of bacteria expressing two distinct half-antibodies. Nat. Biotechnol. 31, 753-758 (2013).
27. Kellner, C., Derer, S., Valerius, T. & Peipp, M. Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions. Methods 65, 105-113 (2014).
28. Roopenian, D.C. & Akilesh, S. FcRn: the neonatal Fc receptor comes of age. Nat. Rev. Immunol. 7, 715-725 (2007).
29. Vink, T., Oudshoorn-Dickmann, M., Roza, M., Reitsma, J.J. & de Jong, R.N. A simple, robust and highly efficient transient expression system for producing antibodies. Methods 65, 5-10 (2014).
30. Bebbington, C.R. Expression of antibody genes in nonlymphoid mammalian cells. Methods 2, 136-145 (1991).
31. Zhao, H. et al. Formulation development of antibodies using robotic system and high-throughput laboratory (HTL). J. Pharm. Sci. 99, 2279-2294 (2010).